Exalenz Bioscience Ltd.

Advisory Board

  • Michael Fried M.D.

    Dr. Fried currently holds the position of Director of the Division of Gastroenterology at the University Hospital in Zurich, Switzerland.

  • Scott L. Friedman , M.D.

    Dr. Friedman is the Fishberg Professor of Medicine, and Chief of the Division of Liver Diseases, Mount Sinai School of Medicine in New York.

  • Didier Samuel, M.D.

    Dr Samuel is Head of the Intensive Care Unit and Liver Unit, Medical Director of the Liver Transplant Program and Consultant Hepatologist at the Paul Brousse Hospital in Paris.

  • Arun Sanyal, M.D.

    Dr. Sanyal, is professor of medicine and chairman, Division of Gastroenterology, at Virginia Commonwealth University Medical Center in Richmond, Virginia.

  • Mitchell L. Shiffman

    Prof. Shiffman is a Prof. Professor of Medicine at the Liver Institute of Virginia, Newport News, VA

  • John M. Vierling , M.D.

    Dr. Vierling., is professor of Medicine and Surgery at the Baylor College of Medicine in Houston, Texas, where he also serves as director of Baylor Liver Health and Chief of Hepatology.

  • Julia Wendon, M.D.

    Dr. Wendon is the head of the Liver Intensive Therapy Unit at Kings College Hospital in London.
2010 Exalenz Bioscience Ltd. All Rights Reserved
Developed by Moonsite

Disclaimer: In the USA, The BreathID System is intended for use in the qualitative detection of H. pylori. It has an approved 510(K) and an approved NDA for the 13 C-urea Tablet and Citrica Powder . Other applications are limited by Federal (of United States) Law to Investigational Use only. In Europe: The BreathID System has a CE approval for assessing Helicobacter pylori, Liver Function, and Gastric Emptying Rate.